Heparin and warfarin were first widely used to treat pulmonary embolism (PE) in the early 1940s. Early acceptance of these drugs was widespread and, in retrospect, rather uncritical. In the face of enthusiastic reports it became very difficult to mount properly controlled trials. Other treatments which evolved in a similar way, and have also been in widespread use, have proved ineffective when formally assessed.
protect the victim of PE from recurrence. In fact, only one patient in the untreated group died from recurrence of PE. Barritt and Jordan are quite emphatic that the benefits of anticoagulants relate to the treatment of established PE rather than to prophylaxis against recurrence: 'It is concluded that when a patient has had a PE, heparin and nicoumalone will reduce the risk of death from that embolism'. They also claim that these drugs will reduce the risk of death from heart failure and diminish the extent of pulmonary infarction. These suggestions are difficult to reconcile with present-day knowledge, that heparin has no thrombolytic action.
Barritt and Jordan were 'impressed by the fact that every patient in this series who received the first injection survived'. This appears to be unduly optimistic as the mortality of PE when treated with heparin in more recent trials has been close to 9% (Tsou 1978) .
The reception which was accorded the Barritt and Jordan paper is revealing. The authors were criticized (Hunter & Walker 1960) for conducting the trial when the benefits of anticoagulants had already been so conclusively demonstrated by Zilliacus in 1946. Analysis of this early work on PE shows that it fails to satisfy elementary requirements of experimental design, such as control of variables. For example, the patients receiving anticoagulants were mobilized after a few days, whereas the untreated patients were subjected to 40 days enforced bed rest. The data from such early studies were retrospective and gathered from numerous sources in the difficult conditions of wartime occupation. The fact that they were considered conclusive suggests an uncritical acceptance on the part of the medical profession of the day.
Johnson & Charnley (1977)
There is only one other prospective controlled trial in the literature, that of Johnson & Charnley (1977) . As this contains by far the largest group of untreated patients of any series, the results are of particular interest (Table I ). There were nearly four times as many recurrent emboli in the treated group (various treatments, heparin, warfarin and combinations of these two drugs). Among the 308 untreated patients there were no deaths. Limitations of the Johnson and Charnley study are that, as with the Barritt and Jordan paper, the diagnosis was made on clinical grounds without the aid of scintigraphy or angiography, and that the study deals with PE in the limited context of surgery for total hip replacement.
Other studies
The bulk of the literature comparing treated with untreated patients is old and generally unsatisfactory. Nevertheless, these papers continue to be quoted, presumably because no more recent work has addressed this problem. For example, a recent authoritative review by Dalen & Alpert (1975) quotes 5 papers (3 of which are now at least 20 years old) in support of the proposition that the mortality of untreated PE is 30% ( Table 2 ). Some of these authors have attempted to circumvent the ethical problem of withholding therapy by taking as the untreated group patients with serious medical contraindications to anticoagulants (Hermann et al. 1961) ,or those whom clinicians had already decided not to treat (Morrell et al. 1954) . It is not surprising that patients deemed desperately ill that anticoagulants were not justified should have died in such large numbers, but one cannot assume from these data that 30% ofall people who have emboli will suffer the same fate if not treated. Two of the papers compare Coon et al. 1969 Oral agents and heparin Browse et al. 1967 Marks et al. 1954 Johnson & Charnley 1977 'We have been disappointed with the use of coumarin drugs in the prevention of further embolism. ' The results obtained in the treatment of pulmonary embolism with oral anticoagulants proved disappointing.' 'Patients who were merely put to bed and given saline had approximately the same incidence of pulmonary embolisation as that which was reported today under treatment.' (p 568 discussion) 'There is a very high recurrence rate in the [anticoagulated) group. The figures are almost identical with those of Barker and Priestley 1942 for the untreated disease.' 'Anticoagulant therapy has not materially influenced the incidence of massive fatal pulmonary embolism.' See Table I treated patients with those who were not treated in the pre-anticoagulant era (Hermann et al. 1961 ,Allen et al. 1947 .These comparisons are oflimited value as the control group antecedes the treated group by periods of up to 20 years.
The papers so far discussed have generally purported to demonstrate reduction in the mortality of PE when anticoagulants are used. However, there are a few studies which have failed to show these benefits (Table 3 ).
Incidence of PE The incidence of PE is not known. It is likely that this disorder is commonly asymptomatic, as normal persons can tolerate sudden occlusion of 50% of the pulmonary vasculature without symptoms (Sabiston et al. 1965) . Coon & Coller (1959) reviewed 4600 consecutive postmortems and found 200 deaths from PE. Only 7% had been diagnosed before death and 75% were clinically unsuspected. In 1976 Coon repeated the study with similar results. Consequently, it is likely that most emboli are undiagnosed and unsuspected.
Mortality of PE Most of the data relating to the death rate from PE in untreated patients concerns a select population, many of whom were not treated because of other diseases. It is misleading to extrapolate these data, as is sometimes done, to young healthy persons, such as pregnant women (de Swiet 1979) .
When PE is diagnosed in a young person there is often general alarm, as the prognosis is considered grave. However, actuarial data suggest that PE in relatively normal persons is a fairly benign condition with a death rate of less than 3 per million (Breckenbridge & Ratnoff 1966) . Use of anticoagulants in these patients is not supported by any published trials and the risk of treatment may significantly outweigh the risk of the disease (Mant et al. 1977) .
The paper by Johnson & Charnley (1977) shows that for patients who have recently had a hip replacement, the mortality of untreated PE is virtually nil. The striking difference between this result and that of the study by Barritt & Jordan (1960) possibly relates to the superior general fitness of the orthopaedic patients. The best predictor of survival in PE is the presence or absence of previous heart disease ( Paraskos et al. 1973) .
When comparing the mortality of treated and untreated patients, many authors overlook the fact that about 75% of fatalities occur within an hour of the onset of symptoms and before treatment can be started (Dalen & Alpert 1975) . If these patients are excluded from the treated group it is not surprising that the effects of 'treatment' are spectacular.
Specific aims of therapy
The traditional mainstay of treatment has been heparin. Various suggestions have been made as to how this drug might work.
Fibrinolysis and the resolution of emboli
Some authorities believe that heparin should be used to enhance the removal of emboli once they have lodged in the pulmonary artery. The rate of resolution of an embolus depends on its age, composition, site of origin, and various host factors, such as age of the patient, previous illnesses and individual differences in fibrinolysis. Scientists who have studied this process in man and animals have been impressed with the speed and efficiency of endogenous fibrinolytic mechanisms (Sautter et al. 1967 , Poe et al. 1967 . In dogs, emboli have substantially resolved within 24 hours without treatment (Mathur et al. 1967) . Seeker-Walker et al. (1970) monitored the progress of PE patients with the use of serial lung scans. They found little difference between the rates of resolution in patients who were treated and those who did not receive treatment because of medical contraindications. Fred et al. (1966) studied 7 patients using serial angiograms: 6 of these subjects were being treated with anticoagulants and their emboli resolved within periods of 7-19 days. One of the shortest resolution times, 7 days, was observed in the patient whose only treatment was plication of the inferior vena cava.
Endogenous fibrinolytic processes appear to be so efficient that there is little point in trying to augment them, except in patients who are dying of the acute effects of pulmonary artery obstruction who may require embolectomy (Lancet 1978) .
Propagation of emboli
Evidence for the propagation of emboli along pulmonary arteries before death is anecdotal. Nevertheless, many authorities feel that anticoagulants should be administered to prevent this possibility.
In 1955 Wessler & Morris were able to prevent experimentally-induced thrombi from extending along the jugular veins of 10 dogs by the use of intravenous heparin in a dose sufficient to maintain the clotting time at twice normal. This observation forms the cornerstone of modern heparin therapy.
Venous and arterial thromboses are different processes (Lancet 1977). Anticoagulants may be effective in preventing venous thrombosis (as opposed to limiting its spread) but, they are ineffective in preventing arterial thrombosis (Thomas 1975) . 'Red' venous thrombi form in conditions of stasis and often in areas of apparently normal endothelium. 'White' arterial thrombi are produced by endothelial damage in regions of turbulent flow (Thomas 1975) . Fibrinogenesis is less active in arterial emboli than in venous thrombi, as shown by the relatively poor uptake of 131 I fibrinogen in the former. Consequently, these two different situations are likely to require different therapeutic strategies.
Theoretical considerations, such as those outlined above, are not a substitute for observations. Marder (1979) , in a small but careful series, studied the evolution of deep venous thromboses (DVTs) with serial quantitative venograms. He found that 4 of 12 DVTs showed significant extension despite full doses of heparin. It would seem that heparin is not a very effective inhibitor of thrombus propagation even in the venous situation.
Bronchospasm.
Several authors have advocated the use of heparin for its antiserotonin properties, to prevent bronchospasm. Bronchospasm following embolization is generally mild and transient and many authorities believe it is not caused by serotonin but by hypocarbia or by other humoral agents (Jaffe & Figley 1967) . Since heparin blocks the release of serotonin from platelets but not the effects of this substance once it has been released, heparin must be administered before the insult if it is to be effective. The effects of serotonin are not all bad, as one of its actions is to activate fibrinolysis (Kwaan et al. 1957 ).
Prevention of recurrence
This is a frequently-stated aim of anticoagulant therapy. The risk of recurrence is uncertain.
Figures for the incidence of fatal recurrence in untreated patients range from 5% (Barritt & Jordan 1960) to 35% (Hermann et al. 1961) . In series which have used angiographic data, the incidence of non-fatal recurrence in treated patients has been 0% (Alpert et al. 1976 )and 19% (Urokinase PE Trial 1973 .
Anyone who has had a DVT or PE has demonstrated susceptibility to thromboembolic disease and is theoretically liable to a second episode. Strictly speaking, there is no good evidence that heparin or warfarin will prevent recurrence of DVT or PE, but the knowledge that phenindione offers effective prophylaxis against a first DVT in certain high-risk patients (Sevitt & Gallagher 1959) may persuade some clinicians to use oral anticoagulants to prevent a recurrence.
Many doctors believe that, in treating PE with anticoagulants, they are effectively 'killing two birds with one stone' -treating the embolus and also dealing with any possible DVT. The author has given his reasons for doubting that anticoagulants have any significant effect on the natural history of the embolus in situ. This leaves the prevention of recurrence as the primary therapeutic goal. Viewed in these terms, the treatment of PE becomes little more than the treatment and prevention of recurrence of DVT. Anticoagulants have a place, but some patients may do better with thrombolytic drugs, surgery, or even conservative management (Browse et al. 1967) .
Prophylaxis of DVT Almost all emboli are thought to start as DVTs, so that prevention of DVT should also prevent emboli. There is good evidence that oral anticoagulants will lower the incidence of DVT in certain high-risk patients, provided they are administered before thrombosis begins (Sevitt & Gallagher 1959) . However, clinicians have been reluctant to use them for this purpose (Morris 1980) . In postsurgical patients, low-dose subcutaneous heparin given to prevent DVT has now been validated in about 30 major trials, and it has also been shown to lower the incidence of fatal PE (Kakkar et al. 1977) .
Every year new approaches to the problem of preventing PE are being explored. Medical treatments which have proved effective include ancrod (Lowe et al. 1978) , dextran (Davies 1978) , dihydroergotamine and heparin (Kakkar et al. 1979) , aspirin and dipyridamole (Renney et al. 1976 ) and intravenous lignocaine (Cooke et al. 1977) .
Since over half of PE deaths occur within 30 minutes of embolization, it is unrealistic to expect that advances in treatment will have a major impact. The best propect of achieving a significant reduction in the mortality of PE is to pay more attention to prophylaxis. It is hard to think of another area of medicine where comparable gains are to be made using existing knowledge.
Hazards of treatment Heparin is the second commonest cause of drug-related hospital deaths in the USA (Porter & Jick 1977) . The incidence of haemorrhagic complications has been as high as.J2% (Mant et al. 1977) . The mortality and morbidity of warfarin are also high.
An often-overlooked hazard of treating PE in a patient who does not have thromboembolic disease is that the true pathology is missed. This may be a treatable disease. At the Auckland Hospital, New Zealand, a recent survey of 500 cases of suspected PE revealed 9 patients who came to post-mortem within 9 days of perfusion scintigraphy. Eight of these patients had been diagnosed as having PE and were on anticoagulants. Emboli were found in only 4 cases. Two patients were receiving anticoagulants (and oral ampicillin) for pneumonia (Egermayer 1980) .
There has been a growing awareness over the last 20 years that PE is a common condition which is often missed. It may be tempting to treat vague symptoms 'just in case'. However, it must be emphasized that anticoagulants are not a harmless anodyne. Before beginning treatment the clinician should ask himself the following questions: (I) How do I know this patient has PE? (2) What will happen if I do not treat him? (3) What are the risks of treatment? (4) What specific pathophysiological processes am I attempting to modify? (5) What are my grounds for believing the treatment is effective? (6) How will I know if my treatment has been successful? Conclusions (1) The scientific basis for the treatment ofPE rests squarely on the paper of Barritt & Jordan (1960) . It is not the intention of the present account to disparage the efforts of these investigators. Their work was a product of the 1950s and much has been learned about the pitfalls of therapeutic trials since then. Barritt and Jordan would probably have been horrified to learn that their modest trial of 19 untreated patients was to be the empirical support for the treatment of hundreds of thousands of patients over the next 20 years.
The author's (intuitive) conclusions are that anticoagulants, in particular warfarin, probably do have some beneficial effect in preventing recurrence of PE (much less than commonly supposed), but that this speculative benefit must be weighed against the known hazards of this form of treatment. Scientific evidence that anticoagulants are beneficial is lacking.
(2) Patients with serious medical illnesses have a high mortality from PE (up to 30%). The prognosis in younger, fitter people is not known. The mortality of treated PE (excluding early deaths) is 9%. (3) PE occurring in patients who have recently undergone total hip replacement should not be treated with anticoagulants. (4) Prevention is better than cure. (5) Urgent research into this area is needed: in particular, a controlled trial of treatment versus conservative management. This has already been done in a limited context by Johnson & Charnley (1977) without adverse effects to the control group. (6) Pending solution of these problems, the use of anticoagulants should be conservative, and greater efforts should be made to establish the diagnosis.
